Welcome to Medivizor!

You're browsing our sample library. Feel free to continue browsing. You can also sign up for free to receive medical information specific to your situation.

Posted by on Mar 27, 2018 in Leukemia | 0 comments

In a nutshell

This study aimed to investigate the safety and effectiveness of nilotinib (Tasigna) in patients with chronic phase chronic myeloid leukemia who have an intolerance to other tyrosine kinase inhibitors.

This study concluded that this group of patients can be treated with nilotinib and it can lead to deep molecular responses.

Some background

Tyrosine kinase inhibitors (TKIs) are a first-line treatment for chronic phase chronic myeloid leukemia (CML-CP). Some patients that receive TKIs can experience intolerable side effects. In these patients, dose adjustments, interrupting or stopping therapy or switching to another TKI is necessary.

It was unknown if nilotinib could be a suitable TKI for these patients.

Methods & findings

This study involved 21 patients with CML-CP who were intolerant of, but responsive to first line TKI treatments imatinib (Gleevec) or dasatinib (Sprycel). Patients were treated with nilotinib for up to 24 months. Patients received 300 mg nilotinib twice daily. The achievement of molecular response (MR)4.5 by 24 months was the main objective. MR is defined as a test result that shows no evidence of abnormal DNA associated with CML-CP.

MR4.5 was achieved by month 24 in 50% of patients after switching to nilotinib.

74% of non-hematological side effects (not in the blood) caused by intolerance to imatinib or dasatinib were resolved within 12 weeks of switching to nilotinib.

The bottom line

This study concluded that CML-CP patients who are intolerant to other TKIs can be treated with nilotinib and it can lead to deep molecular responses.

What’s next?

Consult your physician about nilotinib as a treatment option.

Published By :

Leukemia Research

Date :

Feb 21, 2018

Original Title :

Efficacy and safety of nilotinib 300?mg twice daily in patients with chronic myeloid leukemia in chronic phase who are intolerant to prior tyrosine kinase inhibitors: Results from the Phase IIIb ENESTswift study.

click here to get personalized updates